熊琳++++++徐细明

    [摘要] 目前肝癌的发病率及死亡率呈上升趋势。肝癌发病隐匿，早期诊断困难，进展较快。手术治疗仅可用于不足30%的患者，因此延长患者生存期的非手术治疗显得尤为重要。索拉非尼作為晚期肝癌的非手术治疗方式之一，仅可延长总体生存期数月。晚期肝癌患者超过2/3由于肝内肿瘤进展而死于肝衰竭，局部治疗可以控制肝内肿瘤的进展，但易复发。目前国内外开展了大量索拉非尼联合局部治疗的临床试验。本文通过简述联合治疗的理论以及临床试验的结果，总结出较为可行的结论，为临床医生制订治疗方案提供参考。

    [关键词] 索拉非尼；经皮肝动脉化疗栓塞术；射频消融；放疗；晚期肝癌

    [中图分类号] R73 [文献标识码] A [文章编号] 1673-7210(2017)10(c)-0042-04

    Research progress of Sorafenib combined with locoregional therapy in advanced hepatocellular carcinoma

    XIONG Lin XU Ximing

    Cancer Center， Renmin Hospital of Wuhan University， Hubei Province， Wuhan 430060， China

    [Abstract] At present， the incidence and mortality rate of hepatocellular carcinoma (HCC) are on the rise. HCC is characterized by insidious onset， difficult early diagnosis， and rapid progression. Surgical treatment can only be used for less than 30% of patients， therefore non-surgical treatment used for prolonging the survival time of patients with advanced HCC is significant. As one of the non-surgical treatment of advanced HCC， Sorafenib， can only prolong overall survival time for several months. More than two thirds of patients with advanced HCC have died from liver failure due to the progression of intrahepatic tumors； local treatment can control the progress of intrahepatic tumors ......